Drug intelligence / Profile preview

Trop2 HCAb

Development stage
Unknown
Lead developer
Kisoji Biotechnology
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Trop2 HCAb (Trophoblast cell surface antigen 2 heavy chain-only antibody) refers to a class of fully human single-domain or heavy chain-only antibodies targeting TROP2, a cell-surface glycoprotein overexpressed in various epithelial cancers (such as breast, lung, and colorectal cancers). Unlike conventional antibodies that consist of two heavy and two light chains, HCAbs lack light chains, resulting in a smaller antigen-binding domain (VH or VHH) that can access novel, hard-to-reach epitopes. This format is highly versatile and can be utilized as naked antibodies (such as KisoJi's KJ-103), engineered into multi-specific formats, or used as targeting domains in chimeric antigen receptor (CAR) T-cell therapies. Platforms like Nona Biosciences' Harbour Mice® and KisoJi's KisoMouse™ are used to discover and develop these high-affinity, fully human TROP2-targeting HCAbs to overcome resistance and toxicity challenges associated with traditional TROP2-directed antibody-drug conjugates (ADCs).

Other names
TROP-2 HCAbTROP2 HCAbTROP 2 HCAbTROP-2 heavy chain-only antibodyTROP2 heavy chain-only antibodyTROP 2 heavy chain-only antibodyanti-TROP-2 HCAbanti-TROP2 HCAbanti-TROP 2 HCAbanti-TROP-2 heavy chain-only antibodyanti-TROP2 heavy chain-only antibodyanti-TROP 2 heavy chain-only antibody
02

Targets

TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on Trop2 HCAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trop2 HCAb.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call